Influence of VEGFR and LHCGR on endometrial adenocarcinoma

Kölbl,Alexandra   C.; Birk,Amelie   E.; Kuhn,Christina; Jeschke,Udo; Andergassen,Ulrich

doi:10.3892/ol.2016.4906

Influence of VEGFR and LHCGR on endometrial adenocarcinoma

Authors:
- Alexandra C. Kölbl
- Amelie E. Birk
- Christina Kuhn
- Udo Jeschke
- Ulrich Andergassen
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Ludwig Maximilians University of Munich, D‑80337 Munich, Germany
Published online on: July 22, 2016 https://doi.org/10.3892/ol.2016.4906
Pages: 2092-2098

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Endometrial adenocarcinoma is a common gynecological malignancy that is usually treated by surgical resection followed by radiation. However, the frequency of remote metastasis is high. The present study aimed to investigate whether patients with endometrial adenocarcinoma exhibited a positive response to treatment with a gonadotropin-releasing hormone analogue or inhibitors of neoangiogenesis, which are applied for the treatment of other malignancies. Immunohistochemical analyses were performed using 203 paraffin‑embedded tissue samples of endometrial adenocarcinomas from patients who had undergone surgery at the Department of Obstetrics and Gynecology of the Ludwig Maximilians University of Munich, Germany. The tissues were incubated with antibodies against luteinizing hormone/choriogonadotropin receptor (LHCGR) and vascular endothelial growth factor receptor 2 (VEGFR2), and evaluated by bright field microscopy. The staining was categorized according to the Immune‑Reactive‑Score (IRS). The IRS scores were then statistically associated with various tumor traits, including tumor size, lymph node status, metastasis, grade, expression of steroid hormone receptors and patient survival. There was a significant association between VEGFR2 expression and tumor grading and estrogen receptor‑α (ERα). For LHCGR, a correlation was observed with ERα and progesterone receptor (PR). No correlations were identified between VEGFR2 or LHCGR expression and the other examined tumor traits or patient survival. The associations between VEGFR2 and ERα, and between LHCGR and ERα or PR, may be explained by the interaction of these signal transduction molecules in the regulation of cellular growth and differentiation. These mechanisms also have an important role in the formation of remote metastases, which is the main cause for tumor‑associated mortality. The results of the present study suggested that patients with endometrial adenocarcinoma may benefit from treatment with inhibitors of ERα, PR, VEGFR2 or LHCGR, since it could lead to a better prognosis. However, further studies are required in order to elucidate the roles of these receptors in endometrial adenocarcinoma.

View Figures

View References

1	AGO: Empfehlungen für Diagnostik und Therapie des Endometriumkarzinoms-Aktualisierte Empfehlungen der Kommission Uterus auf Grundlage der S2k Leitlinie (V1.0, 1.6.2008). AWMF Leitlinien Register Nr 0320/342013.
2	GEKID: Cancer in Germany 2005/2006. Incidence and Trends. 2006.
3	Moodley M and Roberts C: Clinical pathway for the evaluation of postmenopausal bleeding with an emphasis on endometrial cancer detection. J Obstet Gynaecol. 24:736–741. 2004. View Article : Google Scholar : PubMed/NCBI
4	Tumorzentrum M: Malignome des Corpus Uteri. Christian PD Dr..Dannecker PMKaPRK: W. Zuckerschwendt Verlag. München, Wien, New York: 2007.
5	Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E and Vergote I: Treatment modalities in endometrial cancer. Curr Opin Oncol. 19:479–485. 2007. View Article : Google Scholar : PubMed/NCBI
6	Beckmann K, Iosifidis P, Shorne L, Gilchrist S and Roder D: Effects of variations in hysterectomy status on population coverage by cervical screening. Aust N Z J Public Health. 27:507–512. 2003. View Article : Google Scholar : PubMed/NCBI
7	Latil A, Bièche I, Pesche S, Valéri A, Fournier G, Cussenot O and Lidereau R: VEGF overexpression in clinically localized prostate tumors and neuropilin-1 overexpression in metastatic forms. Int J Cancer. 89:167–171. 2000. View Article : Google Scholar : PubMed/NCBI
8	Martins SF, Garcia EA, Luz MA, Pardal F, Rodrigues M and Filho AL: Clinicopathological correlation and prognostic significance of VEGF-A, VEGF-C, VEGFR-2 and VEGFR-3 expression in colorectal cancer. Cancer Genomics Proteomics. 10:55–67. 2013.PubMed/NCBI
9	Raspollini MR, Amunni G, Villanucci A, Baroni G, Boddi V and Taddei GL: Prognostic significance of microvessel density and vascular endothelial growth factor expression in advanced ovarian serous carcinoma. Int J Gynecol Cancer. 14:815–823. 2004. View Article : Google Scholar : PubMed/NCBI
10	Olsson AK, Dimberg A, Kreuger J and Claesson-Welsh L: VEGF receptor signalling-in control of vascular function. Nat Rev Mol Cell Biol. 7:359–371. 2006. View Article : Google Scholar : PubMed/NCBI
11	Jubb AM, Hurwitz HI, Bai W, Holmgren EB, Tobin P, Guerrero AS, Kabbinavar F, Holden SN, Novotny WF, Frantz GD, et al: Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol. 24:217–227. 2006. View Article : Google Scholar : PubMed/NCBI
12	Pierce JG and Parsons TF: Glycoprotein hormones: Structure and function. Annu Rev Biochem. 50:465–495. 1981. View Article : Google Scholar : PubMed/NCBI
13	Zygmunt M, Herr F, Keller-Schoenwetter S, Kunzi-Rapp K, Münstedt K, Rao CV, Lang U and Preissner KT: Characterization of human chorionic gonadotropin as a novel angiogenic factor. J Clin Endocrinol Metab. 87:5290–5296. 2002. View Article : Google Scholar : PubMed/NCBI
14	Ji Q, Chen P, Aoyoma C and Liu P: Increased expression of human luteinizing hormone/human chorionic gonadotropin receptor mRNA in human endometrial cancer. Mol Cell Probes. 16:269–275. 2002. View Article : Google Scholar : PubMed/NCBI
15	Lin J, Lei ZM, Lojun S, Rao CV, Satyaswaroop PG and Day TG: Increased expression of luteinizing hormone/human chorionic gonadotropin receptor gene in human endometrial carcinomas. J Clin Endocrinol Metab. 79:1483–1491. 1994. View Article : Google Scholar : PubMed/NCBI
16	Reshef E, Lei ZM, Rao CV, Pridham DD, Chegini N and Luborsky JL: The presence of gonadotropin receptors in nonpregnant human uterus, human placenta, fetal membranes, and decidua. J Clin Endocrinol Metab. 70:421–430. 1990. View Article : Google Scholar : PubMed/NCBI
17	Davies S, Bax CM, Chatzaki E, Chard T and Iles RK: Regulation of endometrial cancer cell growth by luteinizing hormone (LH) and follicle stimulating hormone (FSH). Br J Cancer. 83:1730–1734. 2000. View Article : Google Scholar : PubMed/NCBI
18	Pike MC, Peters RK, Cozen W, Probst-Hensch NM, Felix JC, Wan PC and Mack TM: Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst. 89:1110–1116. 1997. View Article : Google Scholar : PubMed/NCBI
19	Noci I, Pillozzi S, Lastraioli E, Dabizzi S, Giachi M, Borrani E, Wimalasena J, Taddei GL, Scarselli G and Arcangeli A: hLH/hCG-receptor expression correlates with in vitro invasiveness in human primary endometrial cancer. Gynecol Oncol. 111:496–501. 2008. View Article : Google Scholar : PubMed/NCBI
20	Jankowska AG, Andrusiewicz M, Fischer N and Warchol PJ: Expression of hCG and GnRHs and their receptors in endometrial carcinoma and hyperplasia. Int J Gynecol Cancer. 20:92–101. 2010. View Article : Google Scholar : PubMed/NCBI
21	Noci I, Borri P, Bonfirraro G, Chieffi O, Arcangeli A, Cherubini A, Dabizzi S, Buccoliero AM, Paglierani M and Taddei GL: Longstanding survival without cancer progression in a patient affected by endometrial carcinoma treated primarily with leuprolide. Br J Cancer. 85:333–336. 2001. View Article : Google Scholar : PubMed/NCBI
22	Krasnow JS, Berga SL, Guzick DS, Zeleznik AJ and Yeo KT: Vascular permeability factor and vascular endothelial growth factor in ovarian hyperstimulation syndrome: A preliminary report. Fertil Steril. 65:552–555. 1996. View Article : Google Scholar : PubMed/NCBI
23	Neulen J, Yan Z, Raczek S, Weindel K, Keck C, Weich HA, Marmé D and Breckwoldt M: Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor/vascular permeability factor in human granulosa cells: Importance in ovarian hyperstimulation syndrome. J Clin Endocrinol Metab. 80:1967–1971. 1995. View Article : Google Scholar : PubMed/NCBI
24	Robertson D, Selleck K, Suikkari AM, Hurley V, Moohan J and Healy D: Urinary vascular endothelial growth factor concentrations in women undergoing gonadotrophin treatment. Hum Reprod. 10:2478–2482. 1995. View Article : Google Scholar : PubMed/NCBI
25	Koistinen H, Hautala LC, Seppälä M, Stenman UH, Laakkonen P and Koistinen R: The role of glycodelin in cell differentiation and tumor growth. Scand J Clin Lab Invest. 69:452–459. 2009. View Article : Google Scholar : PubMed/NCBI
26	Ohta K, Maruyama T, Uchida H, Ono M, Nagashima T, Arase T, Kajitani T, Oda H, Morita M and Yoshimura Y: Glycodelin blocks progression to S phase and inhibits cell growth: A possible progesterone-induced regulator for endometrial epithelial cell growth. Mol Hum Reprod. 14:17–22. 2008. View Article : Google Scholar : PubMed/NCBI
27	Shabani N, Kuhn C, Kunze S, Schulze S, Mayr D, Dian D, Gingelmaier A, Schindlbeck C, Willgeroth F, Sommer H, et al: Prognostic significance of estrogen receptor alpha (ERalpha) and beta (ERbeta), progesterone receptor A (PR-A) and B (PR-B) in endometrial carcinomas. Eur J Cancer. 43:2434–2444. 2007. View Article : Google Scholar : PubMed/NCBI
28	Remmele W and Stegner HE: Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe. 8:138–140. 1987.(In German). PubMed/NCBI
29	Fan X, Krieg S, Kuo CJ, Wiegand SJ, Rabinovitch M, Druzin ML, Brenner RM, Giudice LC and Nayak NR: VEGF blockade inhibits angiogenesis and reepithelialization of endometrium. FASEB J. 22:3571–3580. 2008. View Article : Google Scholar : PubMed/NCBI
30	Wang J, Taylor A, Showeil R, Trivedi P, Horimoto Y, Bagwan I, Ewington L, Lam EW and El-Bahrawy MA: Expression profiling and significance of VEGF-A, VEGFR2, VEGFR3 and related proteins in endometrial carcinoma. Cytokine. 68:94–100. 2014. View Article : Google Scholar : PubMed/NCBI
31	de Carvalho Fraga CA, Farias LC, de Oliveira MV, Domingos PL, Pereira CS, Silva TF, Roy A, Gomez RS, de Paula AM and Guimarães AL: Increased VEGFR2 and MMP9 protein levels are associated with epithelial dysplasia grading. Pathol Res Pract. 210:959–964. 2014. View Article : Google Scholar : PubMed/NCBI
32	Kampmann E, Altendorf-Hofmann A, Gibis S, Lindner LH, Issels R, Kirchner T and Knösel T: VEGFR2 predicts decreased patients survival in soft tissue sarcomas. Pathol Res Pract. 211:726–730. 2015. View Article : Google Scholar : PubMed/NCBI
33	Higgins KJ, Liu S, Abdelrahim M, Yoon K, Vanderlaag K, Porter W, Metz RP and Safe S: Vascular endothelial growth factor receptor-2 expression is induced by 17beta-estradiol in ZR-75 breast cancer cells by estrogen receptor alpha/Sp proteins. Endocrinology. 147:3285–3295. 2006. View Article : Google Scholar : PubMed/NCBI
34	Higgins KJ, Liu S, Abdelrahim M, Vanderlaag K, Liu X, Porter W, Metz R and Safe S: Vascular endothelial growth factor receptor-2 expression is down-regulated by 17beta-estradiol in MCF-7 breast cancer cells by estrogen receptor alpha/Sp proteins. Mol Endocrinol. 22:388–402. 2008. View Article : Google Scholar : PubMed/NCBI
35	Gargett CE, Zaitseva M, Bucak K, Chu S, Fuller PJ and Rogers PA: 17Beta-estradiol up-regulates vascular endothelial growth factor receptor-2 expression in human myometrial microvascular endothelial cells: Role of estrogen receptor-alpha and- beta. J Clin Endocrinol Metab. 87:4341–4349. 2002. View Article : Google Scholar : PubMed/NCBI
36	Yuri T, Kinoshita Y, Emoto Y, Yoshizawa K and Tsubura A: Human chorionic gonadotropin suppresses human breast cancer cell growth directly via p53-mediated mitochondrial apoptotic pathway and indirectly via ovarian steroid secretion. Anticancer Res. 34:1347–1354. 2014.PubMed/NCBI
37	Brokken LJ, Lundberg-Giwercman Y, De-Meyts Rajpert E, Eberhard J, Ståhl O, Cohn-Cedermark G, Daugaard G, Arver S and Giwercman A: Association of polymorphisms in genes encoding hormone receptors ESR1, ESR2 and LHCGR with the risk and clinical features of testicular germ cell cancer. Mol Cell Endocrinol. 351:279–285. 2012. View Article : Google Scholar : PubMed/NCBI
38	Kundu S, Pramanick K, Paul S, Bandyopadhyay A and Mukherjee D: Expression of LH receptor in nonpregnant mouse endometrium: LH induction of 3β-HSD and de novo synthesis of progesterone. J Endocrinol. 215:151–165. 2012. View Article : Google Scholar : PubMed/NCBI
39	Yung Y, Maman E, Ophir L, Rubinstein N, Barzilay E, Yerushalmi GM and Hourvitz A: Progesterone antagonist, RU486, represses LHCGR expression and LH/hCG signaling in cultured luteinized human mural granulosa cells. Gynecol Endocrinol. 30:42–47. 2014. View Article : Google Scholar : PubMed/NCBI